(Alliance News) - ReNeuron Group PLC announced on Tuesday that Randolph Corteling will re-join the company on March 3, 2022, to lead the research team as vice president of research, reporting directly to the chief executive officer.
Corteling has 24 years experience in medical research and drug discovery, with experience in academia, biotechnology and pharmaceuticals. He has a PhD in medical & surgical sciences from Nottingham University, and was a postdoctoral fellow at the University of Calgary Heart and Stroke Foundation.
He had previously joined the stemcell and exosome technology company in 2007 as a senior member of the research team, then held positions as head of cell biology, and later, head of research.
In 2020, he left to lead disease biology and exosome teams at Evox Therapeutics.
Olav Hellebo, ReNeuron Chief Executive Officer, commented: "We are delighted to welcome Randolph back to ReNeuron. His knowledge and experience in the field of therapeutic exosomes and partnered programmes will be invaluable to us as we seek to continue to build and expand our exosome platform."
ReNeuron's share price fell by 1.8% to 83.00 pence each in London during Tuesday afternoon trading.
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)